Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

University of Toronto

$159,996.00

Commercial Development of Bioengineered Therapeutic Strategy for Spinal Cord Injury

EF 2009-10

Résumé
Individuals with spinal cord injury (SCI) are faced with great emotional, social and financial challenges, and an impaired quality of life due to loss of motor, sensory and autonomic function. With over 1 million patients suffering from chronic spinal cord injury and no effective therapy, the commercial opportunity is significant. Over time, an additional complication occurs where continued degeneration of the cord develops in up to 30% of SCI patients weeks to years after injury. This phenomenon, termed post traumatic syringomyelia (PTS), is debilitating and progressive. PTS is typically associated with scarring in the subarachnoid space which locally obstructs the flow of cerebral spinal fluid that bathes the spinal cord. Animal models of PTS demonstrate that even small areas of subarachnoid scarring can significantly alter fluid flow in the SAS, leading to the formation of a syrinx. Unfortunately, current treatment strategies only work in 50% of patients and even then there is significant recurrence. Current treatment for PTS includes shunting and lysis of subarchnoid adhesions, with recurrence rates as high as 90-100% of cases where focal or extensive arachnoid scarring is present prior to surgery. We have developed an innovative bioengeineered strategy, comprised of a therapeutic polymer, that when delivered to animal models of PTS limits scar formation and the progression of the disease. With a patent application on the composition of matter and its use in spinal cord injury, the commercial opportunity for a product, where none exists, is clear.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
204731
Name
Shoichet Molly S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Commercial Development of Bioengineered Therapeutic Strategy for Spinal Cord Injury
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$159,996
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Animal Models; Bioengineering; Biomaterial Hydrogels; Commercialization; Hyaluronan Methyl Cellulose; Product Development; Spinal Cord Injury; Syringomyelia
Abstract
Individuals with spinal cord injury (SCI) are faced with great emotional, social and financial challenges, and an impaired quality of life due to loss of motor, sensory and autonomic function. With over 1 million patients suffering from chronic spinal cord injury and no effective therapy, the commercial opportunity is significant. Over time, an additional complication occurs where continued degeneration of the cord develops in up to 30% of SCI patients weeks to years after injury. This phenomenon, termed post traumatic syringomyelia (PTS), is debilitating and progressive. PTS is typically associated with scarring in the subarachnoid space which locally obstructs the flow of cerebral spinal fluid that bathes the spinal cord. Animal models of PTS demonstrate that even small areas of subarachnoid scarring can significantly alter fluid flow in the SAS, leading to the formation of a syrinx. Unfortunately, current treatment strategies only work in 50% of patients and even then there is significant recurrence. Current treatment for PTS includes shunting and lysis of subarchnoid adhesions, with recurrence rates as high as 90-100% of cases where focal or extensive arachnoid scarring is present prior to surgery. We have developed an innovative bioengeineered strategy, comprised of a therapeutic polymer, that when delivered to animal models of PTS limits scar formation and the progression of the disease. With a patent application on the composition of matter and its use in spinal cord injury, the commercial opportunity for a product, where none exists, is clear.
Competitiondate
201003
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shoichet, Molly S; Fehlings, Michael G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $159,996~ $0~